{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:49:24Z","timestamp":1745578164799,"version":"3.37.3"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11899-022-00674-4","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T04:02:41Z","timestamp":1660622561000},"page":"217-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Precision Medicine in Myeloid Malignancies: Hype or Hope?"],"prefix":"10.1007","volume":"17","author":[{"given":"Shristi","family":"Upadhyay Banskota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabin","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalyn I.","family":"Marar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.\u00a0N Engl J Med.\u00a02013;368(22):2059\u20132074.","key":"674_CR1","DOI":"10.1056\/NEJMoa1301689"},{"issue":"23","key":"674_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"674_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/CCO.0000000000000673","volume":"32","author":"S UpadhyayBanskota","year":"2020","unstructured":"UpadhyayBanskota S, Khanal N, Bhatt VR. A precision medicine approach to management of acute myeloid leukemia in older adults. Curr Opin Oncol. 2020;32(6):650\u20135.","journal-title":"Curr Opin Oncol"},{"key":"674_CR4","first-page":"1","volume":"40","author":"K Koenig","year":"2020","unstructured":"Koenig K, et al. The changing landscape of treatment in acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"674_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cpt.1962","volume":"108","author":"N Khanal","year":"2020","unstructured":"Khanal N, UpadhyayBanskota S, Bhatt VR. Novel treatment paradigms in acute myeloid leukemia. Clin Pharmacol Ther. 2020;108(3):506\u201314.","journal-title":"Clin Pharmacol Ther"},{"key":"674_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ctrv.2019.04.001","volume":"75","author":"VR Bhatt","year":"2019","unstructured":"Bhatt VR. Personalizing therapy for older adults with acute myeloid leukemia role of geriatric assessment and genetic profiling. Cancer Treat Rev. 2019;75:52\u201361.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"674_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/fon-2021-0260","volume":"18","author":"P Dhakal","year":"2022","unstructured":"Dhakal P, et al. Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age? Future Oncol. 2022;18(3):311\u201321.","journal-title":"Future Oncol"},{"doi-asserted-by":"crossref","unstructured":"Bhatt VR, et al. Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. J Geriatr Oncol 2022.","key":"674_CR8","DOI":"10.1016\/j.jgo.2022.04.005"},{"issue":"1","key":"674_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/asheducation-2017.1.54","volume":"2017","author":"AE Perl","year":"2017","unstructured":"Perl AE. The role of targeted therapy in the management of patients with AML. Hematology. 2017;2017(1):54\u201365.","journal-title":"Hematology"},{"issue":"23","key":"674_CR10","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441\u20139.","journal-title":"Blood"},{"issue":"5","key":"674_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104.","journal-title":"Blood Cancer J"},{"issue":"5","key":"674_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"\u2022\u2022 Stone RM, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364. A phase 3 trial that established addition of midostaurin to intensive chemotherapy as a standard in FLT3 mutated AML.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"674_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood.V130.Suppl_1.721.721","volume":"130","author":"C Rollig","year":"2017","unstructured":"Rollig C, et al. The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled Soraml trial. Blood. 2017;130(Supplement 1):721\u2013721.","journal-title":"Blood"},{"issue":"18","key":"674_CR14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"\u2022\u2022 Perl AE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340. A phase 3 trial that demonstrated gilteritinib to be superior than salvage intensive chemotherapy relapsed or refractory FLT3 mutated AML.","journal-title":"N Engl J Med"},{"issue":"9","key":"674_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"674_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2021-153571","volume":"138","author":"NJ Short","year":"2021","unstructured":"Short NJ, et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a phase I\/II study. Blood. 2021;138(Supplement 1):696\u2013696.","journal-title":"Blood"},{"issue":"2","key":"674_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11(2):25.","journal-title":"Blood Cancer J"},{"issue":"2","key":"674_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11899-009-0011-8","volume":"4","author":"M Malaise","year":"2009","unstructured":"Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2009;4(2):77\u201382.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"674_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hemonc.2016.08.005","volume":"10","author":"H Ayatollahi","year":"2017","unstructured":"Ayatollahi H, et al. Prognostic importance of C-KIT mutations in core binding factor acute myeloid leukemia: a systematic review. Hematol Oncol Stem Cell Ther. 2017;10(1):1\u20137.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"674_CR20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","volume":"4","author":"G Marcucci","year":"2020","unstructured":"Marcucci G, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Adv. 2020;4(4):696\u2013705.","journal-title":"Blood Adv"},{"issue":"7","key":"674_CR21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/s41375-018-0129-6","volume":"32","author":"P Paschka","year":"2018","unstructured":"Paschka P, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia\u2014results of the AMLSG 11\u201308 trial. Leukemia. 2018;32(7):1621\u201330.","journal-title":"Leukemia"},{"issue":"12","key":"674_CR22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27(12):2183\u201391.","journal-title":"Nat Med"},{"issue":"12","key":"674_CR23","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192\u20139.","journal-title":"Nat Med"},{"doi-asserted-by":"crossref","unstructured":"Xue, S., et al., Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT. Leukemia & Lymphoma, 2022 1\u20134.","key":"674_CR24","DOI":"10.1080\/10428194.2022.2064994"},{"issue":"25","key":"674_CR25","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"\u2022 DiNardo CD, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398. This early phase trial demonstrated the role of ivosidenib in relapsed or refractory IDH1 mutated AML.","journal-title":"N Engl J Med"},{"issue":"6","key":"674_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"\u2022 Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. This early phase trial demonstrated the role of enasidenib in relapsed or refractory IDH1 mutated AML.","journal-title":"Blood"},{"issue":"7","key":"674_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"\u2022 Roboz GJ, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371. This early phase trial demonstrated the role of ivosidenib as an initial treated in newly diagnosed IDH1 mutated AML.","journal-title":"Blood"},{"issue":"6","key":"674_CR28","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","volume":"130","author":"MD Amatangelo","year":"2017","unstructured":"Amatangelo MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732\u201341.","journal-title":"Blood"},{"issue":"9","key":"674_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894\u2013905.","journal-title":"Blood Adv"},{"issue":"16","key":"674_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"\u2022\u2022 Montesinos P, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. New England Journal of Medicine. 2022;386(16):1519\u201331. This phase 3 trial demonstrated that a combination of ivosidenib and azacitidine is superior to azacitidine alone in newly diagnosed IDH1 mutated AML.","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"674_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597\u2013608.","journal-title":"Lancet Oncol"},{"issue":"1","key":"674_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10.","journal-title":"Blood Cancer J"},{"issue":"15","key":"674_CR33","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136(15):1707\u201321.","journal-title":"Blood"},{"issue":"6","key":"674_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.19.01406","volume":"38","author":"RF Schlenk","year":"2020","unstructured":"\u2022\u2022 Schlenk RF, et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09\u201309 phase III study. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2020;38(6):623\u201332. This phase 3 trial demonstrated that the addition of gemtuzumab ozogamicin can reduce the risk of relapse in NPM1 mutated AML.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"26","key":"674_CR35","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood.2020005998","volume":"136","author":"S Kapp-Schwoerer","year":"2020","unstructured":"Kapp-Schwoerer S, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09\u201309 trial. Blood. 2020;136(26):3041\u201350.","journal-title":"Blood"},{"issue":"11","key":"674_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803.","journal-title":"Blood"},{"issue":"8","key":"674_CR37","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1080\/10428194.2020.1742908","volume":"61","author":"S Otoukesh","year":"2020","unstructured":"Otoukesh S, et al. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma. 2020;61(8):2020\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"674_CR38","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482\u201395.","journal-title":"Leukemia"},{"key":"674_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/EDBK_199519","volume":"38","author":"A Kuykendall","year":"2018","unstructured":"Kuykendall A, et al. Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book. 2018;38:555\u201373.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"674_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","volume":"32","author":"AM Hunter","year":"2019","unstructured":"Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019;32(2):134\u201344.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"674_CR41","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023\u201336.","journal-title":"N Engl J Med"},{"issue":"7","key":"674_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"\u2022\u2022 DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. This phase 3 trial demonstrated that a combination of venetoclax and azacitidine is superior to azacitidine alone in newly diagnosed AML in older adults.","journal-title":"N Engl J Med"},{"key":"674_CR43","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood-2018-99-119990","volume":"132","author":"DA Sallman","year":"2018","unstructured":"Sallman DA, et al. Phase 1b\/2 combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood. 2018;132:3091.","journal-title":"Blood"},{"key":"674_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/blood-2019-126271","volume":"134","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134:569.","journal-title":"Blood"},{"issue":"5","key":"674_CR45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","volume":"100","author":"M Heuser","year":"2021","unstructured":"\u2022 Heuser M, et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021;100(5):1181\u201394. This phase 2 trial demonstrated that a combination of glasdegib and low-dose cytarabine is superior to low-dose cytarabine alone in newly diagnosed AML in older adults.","journal-title":"Ann Hematol"},{"issue":"1","key":"674_CR46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-020-00929-8","volume":"13","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, et al. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020;13(1):92.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"674_CR47","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"\u2022\u2022 Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481\u201391. This phase 3 trial demonstrated that CPX351 is superior to 7+3 in newly diagnosed high risk or secondary AML in older adults.","journal-title":"Lancet Haematol"},{"issue":"2","key":"674_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176\u201382.","journal-title":"Leukemia"},{"issue":"4","key":"674_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377.","journal-title":"J Clin Oncol"},{"issue":"12","key":"674_CR50","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275\u201391.","journal-title":"Blood"},{"issue":"26","key":"674_CR51","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"12","key":"674_CR52","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890\u20139.","journal-title":"JAMA Oncol"},{"issue":"7","key":"674_CR53","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31(7):1482\u201390.","journal-title":"Leukemia"},{"issue":"14","key":"674_CR54","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1182\/blood.2021013404","volume":"139","author":"GJ Roboz","year":"2022","unstructured":"\u2022\u2022 Roboz GJ, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022;139(14):2145\u201355. This phase 3 trial demonstrated that oral azacitidine maintenance results in survival benefit.","journal-title":"Blood"},{"issue":"12","key":"674_CR55","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood.2018886960","volume":"134","author":"A Venditti","year":"2019","unstructured":"Venditti A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935\u201345.","journal-title":"Blood"},{"issue":"19","key":"674_CR56","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.3390\/ijms221910232","volume":"22","author":"P Lee","year":"2021","unstructured":"Lee P, et al. Molecular targeted therapy and immunotherapy for myelodysplastic syndrome. Int J Mol Sci. 2021;22(19):10232.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"674_CR57","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/bloodadvances.2021004755","volume":"5","author":"N Radakovich","year":"2021","unstructured":"Radakovich N, et al. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021;5(21):4361\u20139.","journal-title":"Blood Adv"},{"issue":"14","key":"674_CR58","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358\u201374.","journal-title":"N Engl J Med"},{"issue":"20","key":"674_CR59","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1182\/blood.2020005488","volume":"136","author":"Y Nagata","year":"2020","unstructured":"Nagata Y, et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood. 2020;136(20):2249\u201362.","journal-title":"Blood"},{"key":"674_CR60","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2021-146932","volume":"138","author":"M Sebert","year":"2021","unstructured":"Sebert M, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group. Blood. 2021;138:62.","journal-title":"Blood"},{"key":"674_CR61","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood-2019-124360","volume":"134","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, et al. Olutasidenib (FT-2102) induces rapid remissions in patients with IDH1-mutant myelodysplastic syndrome: results of phase 1\/2 single agent treatment and combination with azacitidine. Blood. 2019;134:674.","journal-title":"Blood"},{"key":"674_CR62","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/S2152-2650(21)01791-2","volume":"21","author":"S Venugopal","year":"2021","unstructured":"Venugopal S, et al. MDS-090: phase II study of the IDH2 inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). Clinical Lymphoma Myeloma and Leukemia. 2021;21:S339.","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"10","key":"674_CR63","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.3390\/ijms21103432","volume":"21","author":"C Cumbo","year":"2020","unstructured":"Cumbo C, et al. TP53 in myelodysplastic syndromes: recent biological and clinical findings. Int J Mol Sci. 2020;21(10):3432.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"674_CR64","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584\u201394.","journal-title":"J Clin Oncol"},{"issue":"1","key":"674_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.23345","volume":"88","author":"N Daver","year":"2013","unstructured":"Daver N, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013;88(1):56\u20139.","journal-title":"Am J Hematol"},{"issue":"4","key":"674_CR66","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ajh.23924","volume":"90","author":"P Strati","year":"2015","unstructured":"Strati P, et al. Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276\u201381.","journal-title":"Am J Hematol"},{"issue":"4","key":"674_CR67","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3109\/10428194.2012.737917","volume":"54","author":"DA Macdonald","year":"2013","unstructured":"Macdonald DA, et al. A phase I\/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group trial IND186. Leukemia & Lymphoma. 2013;54(4):760\u20136.","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"674_CR68","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"\u2022 Garcia-Manero G, et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674\u201383. This trial supported the approval of oral decitabine.","journal-title":"Blood"},{"issue":"4","key":"674_CR69","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/cancers13040784","volume":"13","author":"S Pagliuca","year":"2021","unstructured":"Pagliuca S, Gurnari C, Visconte V. Molecular targeted therapy in myelodysplastic syndromes: new options for tailored treatments. Cancers. 2021;13(4):784.","journal-title":"Cancers"},{"key":"674_CR70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1182\/blood-2019-124994","volume":"134","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, et al. A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome. Blood. 2019;134:565.","journal-title":"Blood"},{"key":"674_CR71","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2021-145613","volume":"138","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, et al. Molecular responses are observed across mutational spectrum in treatment-na\u00efve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138:241.","journal-title":"Blood"},{"issue":"12","key":"674_CR72","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361.","journal-title":"Cancer"},{"issue":"9","key":"674_CR73","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"674_CR74","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889\u201397.","journal-title":"J Clin Oncol"},{"doi-asserted-by":"crossref","unstructured":"Ngai LL, et al, MRD tailored therapy in AML: what we have learned so far.\u00a0Front\u00a0Oncol.\u00a02021:10.","key":"674_CR75","DOI":"10.3389\/fonc.2020.603636"},{"issue":"21","key":"674_CR76","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1182\/bloodadvances.2018020206","volume":"2","author":"GW Roloff","year":"2018","unstructured":"Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv. 2018;2(21):3070\u201380.","journal-title":"Blood Adv"},{"issue":"12","key":"674_CR77","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd A, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020;26(12):1852\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"674_CR78","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. New Eng J Med. 2021;384(10):924\u201335.","journal-title":"New Eng J Med"},{"issue":"6","key":"674_CR79","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jgo.2021.02.011","volume":"12","author":"VR Bhatt","year":"2021","unstructured":"Bhatt VR. Advances and unanswered questions in management of acute myeloid leukemia in older adults: a glimpse into the future. J Geriatr Oncol. 2021;12(6):980\u20134.","journal-title":"J Geriatr Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00674-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00674-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:25:08Z","timestamp":1669872308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00674-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00674-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"23 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VRB reports participating in Safety Monitoring Committee for Protagonist, and receiving consulting fees from Genentech, Incyte, Servier Pharmaceuticals LLC, and AbbVie; research funding (institutional) from AbbVie, Pfizer, Incyte, Jazz, and National Marrow Donor Program; and drug support (institutional) from Oncoceutics for a trial. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is not an original research article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}